Thus, mTOR inhibitors were a natural choice to test clinically in sarcomas.Rapamycin exert its biological effects by forming a complex with FKBP12 which binds to the FK-rapamycin binding domain of mTOR inhibiting the function of mTORC1-mediated signal pathway and resulting in a direct antiangiogenic effect [58].